2-166002699-C-A
Variant summary
Our verdict is Pathogenic. Variant got 11 ACMG points: 11P and 0B. PM1PM2PP2PP3_StrongPP5_Moderate
The NM_001165963.4(SCN1A):c.4057G>T(p.Val1353Phe) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★).
Frequency
Consequence
NM_001165963.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 11 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SCN1A | ENST00000674923.1 | c.4057G>T | p.Val1353Phe | missense_variant | Exon 24 of 29 | NM_001165963.4 | ENSP00000501589.1 | |||
SCN1A | ENST00000303395.9 | c.4057G>T | p.Val1353Phe | missense_variant | Exon 23 of 28 | 5 | ENSP00000303540.4 | |||
SCN1A | ENST00000375405.7 | c.4024G>T | p.Val1342Phe | missense_variant | Exon 21 of 26 | 5 | ENSP00000364554.3 | |||
SCN1A | ENST00000409050.1 | c.3973G>T | p.Val1325Phe | missense_variant | Exon 21 of 26 | 5 | ENSP00000386312.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Early infantile epileptic encephalopathy with suppression bursts Pathogenic:1
This variant identified in the SCN1A gene is located in the transmembrane spanning D3-S5 region of the resulting protein (PMID: 25348405, 18804930), but it is unclear how this variant impacts the function of this protein. For these reasons, this variant has been classified as Pathogenic. The observation of one or more missense substitutions at this codon (p.Val1353Leu) in affected individuals suggests that this may be a clinically significant residue (PMID: 11254444, 14672992). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has been observed to be de novo in an individual affected with SCN1A-related disease (Invitae). This variant is not present in population databases (ExAC no frequency). This sequence change replaces valine with phenylalanine at codon 1353 of the SCN1A protein (p.Val1353Phe). The valine residue is highly conserved and there is a small physicochemical difference between valine and phenylalanine. -
SCN1A-related disorder Pathogenic:1
The SCN1A c.4057G>T variant is predicted to result in the amino acid substitution p.Val1353Phe. This variant has been reported in an individual with epilepsy, but no additional evidence was provided to support pathogenicity (Truty et al. 2019. PubMed ID: 31440721). This variant is absent from the gnomAD general population database, indicating it is rare. An alternate nucleotide change affecting the same amino acid (c.4057G>C; p.Val1353Leu) has been reported in individuals with generalized epilepsy (Wallace et al. 2001. PubMed ID: 11254444), and functional studies support its pathogenicity (Berecki et al. 2019. PubMed ID: 30779207; Lossin et al. 2003. PubMed ID: 14672992). The c.4057G>T (p.Val1353Phe) variant is documented in ClinVar as pathogenic by one laboratory (https://www.ncbi.nlm.nih.gov/clinvar/variation/577950/), and it has been detected de novo in affected individuals in clinical testing (ClinVar, PreventionGenetics internal data). Taken together, the c.4057G>T (p.Val1353Phe) variant is classified as likely pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at